Company Overview and News

287
BioSpace Movers and Shakers for Week of June 4th

2018-06-12 biospace
Biotech and pharmaceutical companies across the U.S. and globally shook up their senior leadership roles in the first week of June with new hires that included chief executive officers and directors. The companies filled the roles with the talent they believe will drive the next stage of growth.
AUP EVFM PTLA AUPH DARE SRPT TRIL

248
Kane Biotech Appoints Pharmaceutical Executive Rashieda Gluck to Board of Directors

2018-05-22 globenewswire
WINNIPEG, Manitoba, May 22, 2018 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”) is pleased to announce it has appointed Rashieda (Rivka) Gluck to the Corporation’s Board of Directors. With over 20 years of experience in the global pharmaceutical, biotechnology, and life science industries, Ms. Gluck’s career has spanned all levels and functions in clinical development.
AUP KNBIF AUPH KNE

248
Aurinia Pharmaceuticals' (AUPH) CEO Richard Glickman on Q1 2018 Results - Earnings Call Transcript

2018-05-11 seekingalpha
Greetings and welcome to the Aurinia Pharmaceuticals Q1 2017 Financial Results. At this time, all participants are in a listen only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
AUP AUPH

250
Aurinia: Investment Case Gets Stronger

2018-04-04 seekingalpha
Aurinia Pharmaceuticals (NASDAQ:AUPH) recently released its Q4, 2017 results, as well as, provided an update on its pipeline. The company is continuing to progress well with its Phase III AURORA study, which is evaluating lead candidate Voclosporin in lupus nephritis (LN). The company has also expanded its focus area with Voclosporin also being investigated in focal segmental glomerulosclerosis (FSGS) and Voclosporin Opthalmic Solution (VOS) being evaluated in dry eye syndrome (DES).
AUP AUPH

250
Aurnia Pharmaceuticals: Creating Value While Executing Its Business Strategy

2018-03-20 seekingalpha
Aurinia Pharmaceuticals provided a Q4 2017 and full year 2017 earnings call and company update on March 15, 2017.
AUP RTRX AUPH

684
5 Big Biotech Stocks to Buy Under $10

2018-03-20 investorplace
For investors, biotech stocks remain one of the most dynamic sectors out there. On one hand, you have some of the largest pharmaceutical firms on the planet with multi-billion-dollar blockbuster drugs filling their coffers. On the other, you have the more stereotypical “lotto ticket” biotech stocks of clinical or early production stage firms. These are the firms that live and die by the FDA’s decisions and their cash balances.
PIRS AUP AGN DERM AZN VRX AUPH NVAX SNY

249
Aurinia Pharmaceuticals' (AUPH) CEO Richard Glickman on Q4 2017 Results - Earnings Call Transcript

2018-03-16 seekingalpha
Greetings and welcome to the Aurinia Pharmaceuticals Fourth Quarter and Full Year 2017 Financial Results Conference Call. At this time, all participants are in a listen only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
AUP AUPH

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

9h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to TSX:AUP / Aurinia Pharmaceuticals on message board site Silicon Investor.

Hauppauge Digital, Inc. (HAUP) Dauphin Technology
HAUP - Hauppauge Digital HAUP: Hauppauge Digital, Inc.